TriGemX Bio raises $94 million to fund Phase III trials of oral migraine drug elismetrep. Discover the investors backing the program and what comes next.
Astrocyte Pharmaceuticals secures $9.5M Series B funding to advance AST-004 into Phase II trials for concussion and TBI ...
CMS finalized the mandatory GLOBE model, linking Medicare Part B rebates to international drug prices starting in 2027. See ...
Samsung Bioepis and Teva expanded their partnership to develop and commercialize up to six biosimilar candidates. See which ...
Foghorn Therapeutics is cutting about 40% of its workforce after ending FHD-909 and other SMARCA2 programs with Lilly. Read ...
Progentos begins Phase I/II human trial of oral PRO-1562 for multiple sclerosis remyelination. First-in-human study ...
Atara Biotherapeutics resubmits tabelecleucel BLA to FDA for EBV+ post-transplant lymphoproliferative disease. Latest updates ...
Regeneron and Sanofi expand antibody alliance with $1B upfront and $7B in milestones for IL-4/IL-13 pathway treatments. Learn ...
NRx Pharmaceuticals wins $11.2M DARPA funding to test NRX-101 combined with robotic TMS for treatment-resistant depression.
Eli Lilly's retatrutide shows 20.8% weight loss and A1C improvements in type 2 diabetes. TRIUMPH-2 trial results presented at ...
Varda Space Industries secures $251M Series D funding to scale space-based pharmaceutical manufacturing. Learn how orbital ...
Roche's fenebrutinib receives FDA priority review for relapsing and primary progressive MS. First BTK inhibitor filing for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results